A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination

被引:212
作者
Verstraeten, T
Jumaan, AO
Mullooly, JP
Seward, JF
Izurieta, HS
DeStefano, F
Black, SB
Chen, RT
机构
[1] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Epidemiol Program Off, Atlanta, GA USA
[2] Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA
[3] NW Kaiser Permanente, Ctr Hlth Res, Portland, OR USA
[4] Pan Amer Hlth Org, Washington, DC USA
[5] No Calif Kaiser Permanente, Pediat Vaccine Study Ctr, Oakland, CA USA
关键词
varicella vaccine; asthma; steroids; measles-mumps-rubella vaccine; chickenpox;
D O I
10.1542/peds.112.2.e98
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective. Varicella breakthrough, the occurrence of varicella disease >42 days after vaccination, is indicative of vaccination failure. A sevenfold increased risk of breakthrough among vaccinated children with asthma was observed in a 1996 varicella outbreak in a child care center. More recent outbreak investigations have also identified age at vaccination as a potential risk factor for breakthrough. We assessed the association of varicella breakthrough with asthma, steroids, age at varicella vaccination, and timing of measles-mumps-rubella (MMR) vaccination. Methods. We performed a retrospective cohort study among children born after 1993 and followed up through 1999 at 2 health maintenance organizations ([HMOs] A and B) in the United States. Information was obtained from automated vaccination, clinic, hospital discharge, and pharmacy records. Results. We identified 268 and 97 breakthrough cases among 80 584 and 8181 children vaccinated against varicella at HMOs A and B, respectively. Varicella breakthrough was not associated with asthma, inhaled steroids prescribed at any time, and oral steroids prescribed before vaccination. An increased risk of varicella breakthrough was found in the 3 months immediately after prescription for oral steroids at HMO A (adjusted relative risk [aRR]: 2.4; 95% confidence interval [CI]: 1.3-4.4) and HMO B (aRR: 2.8; 95% CI: 1.0-7.8), when varicella vaccine was given before 15 months of age at HMO A (aRR: 1.4; 95% CI: 1.1-1.9), and when varicella vaccination followed MMR vaccine within 28 days at HMO A (aRR: 3.1; 95% CI: 1.5-6.4). Conclusions. Varicella vaccine failure in children was not associated with asthma or the use of inhaled steroids, but with the use of oral steroids. Administration of varicella vaccine before the age of 15 months may be associated with a slightly increased risk of breakthrough disease. As currently recommended, varicella vaccination should not be administered for 28 days after MMR vaccination.
引用
收藏
页码:E98 / E103
页数:6
相关论文
共 38 条
[1]  
BALFOUR HH, 1988, AM J MED, V85, P68
[2]   Could asthma be worsened by stimulating the T-helper type 1 immune response? [J].
Castro, M ;
Chaplin, DD ;
Walter, MJ ;
Holtzman, MJ .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 22 (02) :143-146
[3]  
*CDCP, 2002, MMWR-MORBID MORTAL W, V51, P664
[4]  
*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P682
[5]   Clinical efficacy of a vaccine-immunostimulant combination in the prevention of influenza in patients with chronic obstructive pulmonary disease and chronic asthma [J].
Centanni, S ;
Pregliasco, F ;
Bonfatti, C ;
Mensi, C ;
Tarsia, P ;
Guarnieri, R ;
Allegra, L .
JOURNAL OF CHEMOTHERAPY, 1997, 9 (04) :273-278
[6]  
Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P1
[7]  
Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P1058
[8]  
Chen RT, 2000, B WORLD HEALTH ORGAN, V78, P186
[9]   Vaccine Safety Datalink project: A new tool for improving vaccine safety monitoring in the United States [J].
Chen, RT ;
Glasser, JW ;
Rhodes, PH ;
Davis, RL ;
Barlow, WE ;
Thompson, RS ;
Mullooly, JP ;
Black, SB ;
Shinefield, HR ;
Vadheim, CM ;
Marcy, SM ;
Ward, JI ;
Wise, RP ;
Wassilak, SG ;
Hadler, SC ;
Swint, E ;
Hardy, JR ;
Payne, T ;
Immanuel, V ;
Benson, P ;
Draket, J ;
Drew, L ;
Mendius, B ;
Ray, P ;
Lewis, N ;
Fireman, BH ;
Jing, J ;
Wulfsohn, M ;
Lugg, MM ;
Osborne, P ;
Rastogi, S ;
Patriarca, P ;
Caserta, V .
PEDIATRICS, 1997, 99 (06) :765-773
[10]   ALLERGEN EXPOSURE INDUCES THE ACTIVATION OF ALLERGEN-SPECIFIC TH2 CELLS IN THE AIRWAY MUCOSA OF PATIENTS WITH ALLERGIC RESPIRATORY DISORDERS [J].
DELPRETE, GF ;
DECARLI, M ;
DELIOS, MM ;
MAESTRELLI, P ;
RICCI, M ;
FABBRI, L ;
ROMAGNANI, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (07) :1445-1449